PHARMACOKINETICS OF FIRST-IN-CLASS N-MYRISTOYLATION INHIBITOR PCLX-001 IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID
$1,401,871FY2022Defense Health AgencyDOD
The Univeristy Of Texas M.D. Anderson Cancer Center
The Univeristy Of Texas M.D. Anderson Cancer Center